Molecular Weight(MW): 271.64
INCB024360 analogue is a potent, competitive IDO1 (indoleamine-(2,3)-dioxygenase) inhibitor with IC50 of 67 nM. Phase 2.
Purity & Quality Control
Choose Selective IDO Inhibitors
Click to view more
2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
|Description||INCB024360 analogue is a potent, competitive IDO1 (indoleamine-(2,3)-dioxygenase) inhibitor with IC50 of 67 nM. Phase 2.|
In HeLa cells, INCB024360 shows higher inhibitory activity on IDO1 with IC50 of 19 nM.  In coculture systems of human allogeneic lymphocytes with dendritic cells or tumor cells, INCB024360, via IDO1 inhibition, reverses T-cell suppression mediated by IDO-expressing HeLa cells or DCs, and increases the proliferation and functional activity of CD4+ T cells, CD8+ T cells, and NK cells. 
|In vivo||In mice bearing GM-CSF-secreting B16 tumors, INCB024360 (75 mg/kg b.i.d) causes dose dependent inhibition of tumor growth.  INCB024360 significantly suppresses tumor growth in immunocompetent, but not immunodeficient, mice. |
|In vitro||DMSO||54 mg/mL warmed (198.79 mM)|
|Ethanol||54 mg/mL warmed (198.79 mM)|
|In vivo||5% DMSO+45% PEG 300+ddH2O||22mg/mL|
* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02862457||Recruiting||Neoplasms||Merck Sharp & Dohme Corp.||August 2016||Phase 1|
|NCT02785250||Recruiting||Recurrent Epithelial Ovarian Cancer|Recurrent Fallopian Tube Cancer|Recurrent Peritoneal Cancer||ImmunoVaccine Technologies, Inc.|Incyte Corporation||April 2016||Phase 1|
|NCT02575807||Recruiting||Platinum-resistant Ovarian Cancer|Platinum-resistant Fallopian Cancer|Platinum-resistant Peritoneal Cancer||Aduro Biotech, Inc.|Incyte Corporation||January 2016||Phase 1|Phase 2|
|NCT02318277||Recruiting||Selected Advanced Solid Tumors|Non-small Cell Lung Cancer|Melanoma|Head and Neck Cancer|Gastric Cancer|Gastroesophageal Cancer|Urothelial Cancer|Triple Negative Breast Cancer||Incyte Corporation|MedImmune LLC||December 2014||Phase 1|Phase 2|
|NCT02178722||Recruiting||Malignant Solid Tumor|Lymphoma, Large B-Cell, Diffuse|Carcinoma, Non-Small-Cell Lung|Transitional Cell Carcinoma of Urinary Tract|Triple Negative Breast Cancer|Carcinoma, Squamous Cell of Head and Neck|Ovarian Neoplasms|Adenocarcinoma of the Endometrium|Renal Cell Carcinoma|Microsatellite-instability (MSI) High Colorectal Cancer||Incyte Corporation|Merck Sharp & Dohme Corp.||June 2014||Phase 1|Phase 2|
|NCT02118285||Suspended||Ovarian Cancer|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma||Masonic Cancer Center, University of Minnesota|Incyte Corporation||April 2014||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.